Artiva Biotherapeutics (NASDAQ:ARTV) CEO Fred Aslan Sells 25,500 Shares

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) CEO Fred Aslan sold 25,500 shares of Artiva Biotherapeutics stock in a transaction on Friday, August 15th. The shares were sold at an average price of $2.73, for a total transaction of $69,615.00. Following the sale, the chief executive officer directly owned 386,693 shares of the company’s stock, valued at $1,055,671.89. This trade represents a 6.19% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Artiva Biotherapeutics Price Performance

Shares of NASDAQ:ARTV opened at $2.71 on Thursday. The firm has a fifty day moving average of $2.31 and a two-hundred day moving average of $2.84. Artiva Biotherapeutics, Inc. has a 12-month low of $1.47 and a 12-month high of $17.31.

Artiva Biotherapeutics (NASDAQ:ARTV) last issued its earnings results on Wednesday, August 6th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.03). On average, equities analysts predict that Artiva Biotherapeutics, Inc. will post -4.95 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on ARTV shares. HC Wainwright upgraded shares of Artiva Biotherapeutics to a “buy” rating and set a $12.00 price target on the stock in a report on Wednesday, June 11th. Needham & Company LLC cut their price target on shares of Artiva Biotherapeutics from $23.00 to $18.00 and set a “buy” rating on the stock in a report on Thursday, May 15th. Four research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of $17.00.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of ARTV. JPMorgan Chase & Co. raised its holdings in Artiva Biotherapeutics by 250.7% in the 4th quarter. JPMorgan Chase & Co. now owns 37,619 shares of the company’s stock worth $379,000 after acquiring an additional 26,893 shares during the period. Geode Capital Management LLC raised its holdings in Artiva Biotherapeutics by 2.2% in the 4th quarter. Geode Capital Management LLC now owns 315,758 shares of the company’s stock worth $3,184,000 after acquiring an additional 6,828 shares during the period. Wells Fargo & Company MN raised its holdings in Artiva Biotherapeutics by 64.0% in the 4th quarter. Wells Fargo & Company MN now owns 8,616 shares of the company’s stock worth $87,000 after acquiring an additional 3,361 shares during the period. Barclays PLC raised its holdings in Artiva Biotherapeutics by 23.2% in the 4th quarter. Barclays PLC now owns 24,161 shares of the company’s stock worth $244,000 after acquiring an additional 4,545 shares during the period. Finally, Northern Trust Corp raised its holdings in Artiva Biotherapeutics by 3.8% in the 4th quarter. Northern Trust Corp now owns 117,112 shares of the company’s stock worth $1,180,000 after acquiring an additional 4,335 shares during the period.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.